May 9, 2017. We strongly support FDA efforts to strengthen the role of patients and we urge the agency to define patients as those who use medical products, whether or not they are seriously ill.
Read More »On Health Policy
Letter to Pruitt Concerning Beck Hiring for Senior Position at EPA
The National Center for Health Research and 24 other organizations have expressed concern over Dr. Nancy Beck’s appointment to a senior position at the EPA, highlighting her previous role at the American Chemistry Council and potential conflicts of interest that could influence the agency’s chemical safety policies.
Read More »NCHR Comment on the USPSTF’s Draft Recommendations for Prostate Cancer Screening
May 8, 2017. We support the efforts of the U.S. Preventive Services Task Force (USPSTF) to re-evaluate its recommendations in light of new research regarding prostate cancer screening that provides new insights into its benefits and risks.
Read More »NCHR Testimony to the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria on Animal Antibiotics
May 4, 2017. We support efforts by federal agencies to reduce unnecessary exposures to antibiotics. Reducing unnecessary exposure reduces antibiotic resistance, and thus preserves the use of these antibiotics for animal and human health.
Read More »NCHR Testimony at FDA Meeting on Developing Antibiotics for Bacteria That Rarely Cause Infection
Stephanie Fox-Rawlings, April 13 2017: At an FDA meeting, NCHR explained that developing new antibiotics for rare, low-risk bacteria could do more harm than good by exposing patients to unnecessary side effects, increasing the chances of drug-resistant infections, and diverting resources away from treatments that are truly needed.
Read More »